Diligence memo · auto-generated · as of July 2, 2026
Genesis Therapeutics, Inc.
Genesis Therapeutics, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Genesis Therapeutics, Inc. operates in Biotechnology, based in BURLINGAME.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Genesis Therapeutics, Inc. has raised $297M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $224M on 2023-08-10.
Most recent recorded round closed around 2023-08-10.
Valuation (modeled)modeled
Provath models Genesis Therapeutics, Inc. at approximately $3.3B (range $1.0B–$5.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.64× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 2.9 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 9.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 98% of Biotechnology peers (4293 compared).
Modeled value ranks above 97% of those peers.
Closest niche peers: Areteia Therapeutics, Inc., GIO World Health Ltd, Crinetics Pharmaceuticals, Inc., 2seventy bio, Inc., Gio World Health (Europe) Sa.
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.